BCMA-directed therapy for early relapsed and/or refractory multiple myeloma

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-07-19 DOI:10.1038/s41571-024-00927-6

Niels W. C. J. van de Donk, Sonja Zweegman

引用次数: 0

Abstract

BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.

Abstract Image

查看原文本刊更多论文

针对早期复发和/或难治性多发性骨髓瘤的BCMA导向疗法。

BCMA靶向嵌合抗原受体T细胞疗法和双特异性T细胞捕获剂正在成为多发性骨髓瘤的早期疗法。此外，在首次复发或复发后使用BCMA靶向抗体-药物共轭物贝仑单抗马福多汀进行联合治疗，也有可能提高该病患者的生存率。越来越多的治疗选择使得治疗方案的选择和排序变得越来越复杂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.